Philip Vlummens
Overview
Explore the profile of Philip Vlummens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
613
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
de Veirman K, Puttemans J, Krasniqi A, Ertveldt T, Hanssens H, Romao E, et al.
Oncoimmunology
. 2021 Nov;
10(1):2000699.
PMID: 34777918
Multiple myeloma (MM) is a hematological malignancy characterized by the presence of clonal plasma cells in the bone marrow niche. Despite significant therapeutic advances, MM remains incurable for the majority...
12.
Tremblay G, Daniele P, Breeze J, Li L, Shah J, Shacham S, et al.
BMC Cancer
. 2021 Sep;
21(1):993.
PMID: 34488662
Background: Selinexor is an oral, selective nuclear export inhibitor. STORM was a phase 2b, single-arm, open-label, multicenter trial of selinexor with low dose dexamethasone in patients with penta-exposed relapsed/refractory multiple...
13.
Harrison S, Perrot A, Alegre A, Simpson D, Wang M, Spencer A, et al.
Br J Haematol
. 2021 May;
194(1):120-131.
PMID: 34036560
Treatment benefit in multiple myeloma (MM) patients with high-risk cytogenetics remains suboptimal. The phase 3 ICARIA-MM trial (NCT02990338) showed that isatuximab plus pomalidomide-dexamethasone prolongs median progression-free survival (mPFS) in patients...
14.
De Smedt E, Devin J, Muylaert C, Robert N, Requirand G, Vlummens P, et al.
Blood Adv
. 2021 May;
5(9):2325-2338.
PMID: 33938943
Multiple myeloma (MM) is an (epi)genetic highly heterogeneous plasma cell malignancy that remains mostly incurable. Deregulated expression and/or genetic defects in epigenetic-modifying enzymes contribute to high-risk disease and MM progression....
15.
Cohen Y, Oriol A, Wu K, Lavi N, Vlummens P, Jackson C, et al.
Clin Lymphoma Myeloma Leuk
. 2021 Jan;
21(1):46-54.e4.
PMID: 33485428
Background: Daratumumab is approved for relapsed or refractory multiple myeloma (RRMM) as monotherapy or in combination regimens. We evaluated daratumumab plus cetrelimab, a programmed death receptor-1 inhibitor, in RRMM. Patients...
16.
Janssens E, Van Dorpe J, Van Hende V, Moors I, Vlummens P, De Vriendt C
Acta Clin Belg
. 2021 Jan;
77(2):410-415.
PMID: 33433292
A 61-year-old female presented with pancytopenia with a hemoglobin of 7.6 g/dL, platelet count of 26.000/µL and neutrophil count of 525/µL. Bone marrow aspirate showed moderately cellular marrow with a...
17.
Van Landeghem S, Capiau S, Bayart J, Vlummens P, Van Dorpe J, Van Roy N, et al.
Clin Case Rep
. 2020 Dec;
8(12):3070-3074.
PMID: 33363882
This report highlights the importance of integrating clinical, radiological, genetic, and pathological laboratory findings to make a correct diagnosis especially with challenging and rare entities.
18.
Faict S, Oudaert I, dAuria L, Dehairs J, Maes K, Vlummens P, et al.
Cancers (Basel)
. 2019 Nov;
11(12).
PMID: 31756922
Multiple myeloma (MM) is well-known for the development of drug resistance, leading to relapse. Therefore, finding novel treatment strategies remains necessary. By performing a lipidomics assay on MM patient plasma,...
19.
Maes A, Maes K, Vlummens P, De Raeve H, Devin J, Szablewski V, et al.
Blood Cancer J
. 2019 Nov;
9(12):87.
PMID: 31740676
Diffuse large B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) are among the most aggressive B cell non-Hodgkin lymphomas. Maternal embryonic leucine zipper kinase (MELK) plays a role in...
20.
Vlummens P, de Veirman K, Menu E, de Bruyne E, Offner F, Vanderkerken K, et al.
Front Genet
. 2019 Sep;
10:740.
PMID: 31475039
Multiple myeloma (MM) is a B-cell malignancy characterized by the accumulation of clonal plasma cells in the bone marrow. In normal plasma cell development, cells undergo programmed DNA breaks and...